Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024
August 01 2024 - 6:30AM
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:
AVXL), a clinical-stage biopharmaceutical company developing
differentiated therapeutics for the treatment of Alzheimer's
disease, Parkinson's disease, schizophrenia, neurodevelopmental,
neurodegenerative, and rare diseases, including Rett syndrome and
other central nervous system (CNS) diseases, today announced that
it will issue financial results for its fiscal quarter ended June
30, 2024, on Tuesday, August 6, 2024.
Management will host a conference call on
Tuesday, August 6, 2024, at 8:30 am ET to review financial results
and provide an update on the execution of the Company’s growth
strategy. Following management’s remarks, there will be a
question-and-answer session.
Webcast / Conference Call Information:
The live webcast of the conference call will be available on
Anavex’s website at www.anavex.com.
The conference call can be also accessed by
dialing 1 929 205 6099 for participants in the U.S. using the
Meeting ID# 821 9280 7728 and reference passcode 121725. A replay
of the conference call will also be available on Anavex’s website
for up to 30 days.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of novel therapeutics for the treatment of
neurodegenerative, neurodevelopmental, and neuropsychiatric
disorders, including Alzheimer's disease, Parkinson's disease, Rett
syndrome, schizophrenia and other central nervous system (CNS)
diseases, pain, and various types of cancer. Anavex's lead drug
candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a
Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a
Phase 2 proof-of-concept study in Parkinson's disease dementia, and
both a Phase 2 and a Phase 3 study in adult patients and one Phase
2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is
an orally available drug candidate that restores cellular
homeostasis by targeting SIGMAR1 and muscarinic receptors.
Preclinical studies demonstrated its potential to halt and/or
reverse the course of Alzheimer's disease. ANAVEX®2-73 also
exhibited anticonvulsant, anti-amnesic, neuroprotective, and
anti-depressant properties in animal models, indicating its
potential to treat additional CNS disorders, including epilepsy.
The Michael J. Fox Foundation for Parkinson's Research previously
awarded Anavex a research grant, which fully funded a preclinical
study to develop ANAVEX®2-73 for the treatment of Parkinson's
disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1
muscarinic receptors, is a promising clinical stage drug candidate
demonstrating disease-modifying activity against the major
hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice,
including cognitive deficits, amyloid, and tau pathologies. In
preclinical trials, ANAVEX®3-71 has shown beneficial effects on
mitochondrial dysfunction and neuroinflammation. Further
information is available at www.anavex.com. You can also connect
with the Company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:Anavex
Life Sciences Corp.Research & Business DevelopmentToll-free:
1-844-689-3939Email: info@anavex.com
Investors:Andrew J.
BarwickiInvestor Relations
Tel: 516-662-9461Email: andrew@barwicki.com
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Sep 2023 to Sep 2024